摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-(氨基甲基)噻唑-2-基)氨基甲酸叔丁酯 | 878376-13-7

中文名称
(5-(氨基甲基)噻唑-2-基)氨基甲酸叔丁酯
中文别名
N-[5-(氨基甲基)-1,3-噻唑-2-基]氨基甲酸叔丁酯
英文名称
tert-butyl [5-(aminomethyl)-1,3-thiazol-2-yl]carbamate
英文别名
Tert-butyl N-[5-(aminomethyl)-1,3-thiazol-2-yl]carbamate
(5-(氨基甲基)噻唑-2-基)氨基甲酸叔丁酯化学式
CAS
878376-13-7
化学式
C9H15N3O2S
mdl
——
分子量
229.303
InChiKey
BJBOIRJERIUSFM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.265±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    106
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (5-(氨基甲基)噻唑-2-基)氨基甲酸叔丁酯间氟苯甲酰氯三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 0.67h, 以100%的产率得到tert-butyl (5-{[(3-fluorobenzoyl)amino]methyl}-1,3-thiazol-2-yl)carbamate
    参考文献:
    名称:
    Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors
    摘要:
    The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory activity and excellent selectivity against a panel of various serine-threonine and tyrosine kinases, as exemplified by compound 46. We found also that the position and nature of the substituent on the thiazole play key roles in cellular potency. Compounds with an acetanilide substituent at C5' have the greatest cellular activity. The importance of the C5' position for substitution has been rationalized by ab initio molecular orbital calculations. Results show that the planar conformation with the sulfur of the thiazole next to the quinazoline N-3 is strongly favored over the other possible planar conformation. Compound 46 is a potent suppressor of the expression of phospho-histone H3 in tumor cells in vitro as well as in vivo, where 46, administered as its phosphate prodrug 54, suppresses the expression of phospho-histone H3 in subcutaneously implanted tumors in nude mice.
    DOI:
    10.1021/jm050786h
  • 作为产物:
    参考文献:
    名称:
    Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors
    摘要:
    The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory activity and excellent selectivity against a panel of various serine-threonine and tyrosine kinases, as exemplified by compound 46. We found also that the position and nature of the substituent on the thiazole play key roles in cellular potency. Compounds with an acetanilide substituent at C5' have the greatest cellular activity. The importance of the C5' position for substitution has been rationalized by ab initio molecular orbital calculations. Results show that the planar conformation with the sulfur of the thiazole next to the quinazoline N-3 is strongly favored over the other possible planar conformation. Compound 46 is a potent suppressor of the expression of phospho-histone H3 in tumor cells in vitro as well as in vivo, where 46, administered as its phosphate prodrug 54, suppresses the expression of phospho-histone H3 in subcutaneously implanted tumors in nude mice.
    DOI:
    10.1021/jm050786h
点击查看最新优质反应信息

文献信息

  • [EN] QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS À SUBSTITUTION PAR CATIONS AMMONIUM QUATERNAIRES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
    申请人:[en]F. HOFFMANN-LA ROCHE AG
    公开号:WO2023280733A1
    公开(公告)日:2023-01-12
    The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1to R6are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
查看更多